# Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

> **NCT02847728** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1189 (actual)

## Conditions studied

- Melanoma
- Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02847728
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-28
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 1189 (ACTUAL)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02847728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02847728, "Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02847728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*